Henlius Wins EMA Panel Backing for Denosumab Biosimilar HLX14; Shares Gain 4%
MT Newswires Live
Jul 29
Shanghai Henlius Biotech (HKG:2696) said its denosumab biosimilar HLX14 has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, supporting its approval for use across the EU, according to a Monday Hong Kong bourse filing.
Shares of the company rose nearly 4% in Tuesday's recent trade.
The biosimilar targets osteoporosis and bone complications from cancer.
Final approval from the European Commission is expected in two to three months, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.